Seven Eight Capital, LP Grifols Sa Transaction History

Seven Eight Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 06, 2020	SELL	$18.24 - $21.45 $227,252 - $267,245	-12,459 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$16.28 - $25.63 $1.12 Million - $1.77 Million	-69,013 Reduced 84.71%	12,459 $251,000
Q4 2019 Feb 13, 2020	SELL	$19.57 - $23.52 $657,552 - $790,272	-33,600 Reduced 29.2%	81,472 $1.9 Million
Q3 2019 Nov 14, 2019	BUY	$19.85 - $22.76 $2.28 Million - $2.62 Million	115,072 New	115,072 $2.31 Million

147

151M

2.38M

662K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.57B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.